Biosimilars sector Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
00:42
Feb 09
Feb 09
Celltrion benefits from biosimilar drug-price push.
Trump's push to lower drug prices is pressuring biotech broadly, but biosimilars are an exception because PBMs need them to reduce drug costs. Celltrion is showing relative strength, and the market is paying attention to biosimilar names.
MED
About Biosimilars sector Investor Commentary
Across the available history and selected sources, Buzzberg tracks Biosimilars sector across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Jang Woo-jin.